Myriad Genetics, a leading company in molecular diagnostics and precision medicine, has launched a new global partnership with SOPHiA GENETICS, an AI-driven healthcare technology firm. This partnership aims to create and provide a next-generation liquid biopsy companion diagnostic (CDx) test. The goal of this collaboration is to support pharmaceutical companies worldwide by combining Myriad’s advanced laboratory operations in the U.S. with SOPHiA GENETICS’ extensive, decentralized network of over 800 institutions in 70 countries. This will help support global clinical trial testing and make innovative diagnostic tools more accessible globally.
Health Technology Insights: Lindus and Frieda Complete Menopause Treatment Trial
Sam Raha, President and CEO of Myriad Genetics, highlighted that this collaboration supports the company’s broader mission of improving care for cancer patients. He explained that by working with SOPHiA GENETICS, Myriad can add valuable testing options to its portfolio and help its biopharma partners bring new, targeted therapies to market. Raha also mentioned that this joint effort could make a significant difference in patients’ lives and help expand Myriad’s companion diagnostic programs.
Health Technology Insights: RazorMetrics Saves Texans $34 Million on Prescriptions in 2 years
The first project will focus on MSK-ACCESS powered by SOPHiA DDM, a liquid biopsy test developed in partnership with Memorial Sloan Kettering Cancer Center. This test can detect important genetic changes by analyzing circulating tumor DNA through a simple blood draw using advanced algorithms. Using this tool as a companion diagnostic means more patients can benefit from precision oncology care by accessing comprehensive tumor profiling through non-invasive methods.
As part of the collaboration, Myriad will manage regulatory processes in the United States, while SOPHiA GENETICS will handle international regulatory submissions. Both companies will work closely together throughout the development process. The approach is intended to create a global framework that helps pharmaceutical companies efficiently and consistently reach key regulated markets.
Jurgi Camblong, CEO and Co-founder of SOPHiA GENETICS, called the collaboration a major milestone for the diagnostics and pharmaceutical industries. He said that by combining Myriad’s specialized lab services with SOPHiA’s global testing infrastructure, the partnership will increase access to advanced oncology testing. Camblong added that this effort also introduces a new hybrid model in companion diagnostics that can meet the needs of both clinical and pharmaceutical partners, helping to speed up the adoption of liquid biopsy technologies around the world.
Health Technology Insights: Fitnescity Health launches CT Calcium Score test platform
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
